Major Bleeding Risk During Concomitant Use of Antiarrhythmic Drugs and Oral Factor Xa Inhibitors: A Nationwide Self-Controlled Case Series Study
Concomitant use of FXa inhibitors with amiodarone, diltiazem, or verapamil was related to an increased incidence of major bleeding, particularly during the first month of co-administration. Close monitoring during this period may be warranted for patients at high risk of bleeding.
Authors
- Kyu‐Nam Heo (ORCID: https://orcid.org/0000-0003-3626-3999)
- Jaekyu Shin (ORCID: https://orcid.org/0000-0002-7097-9977)
- Ju‐Yeun Lee (ORCID: https://orcid.org/0000-0002-2261-7330)
- YooJung Choi (ORCID: https://orcid.org/0009-0009-8102-4170)
- Jonghyun Jeong (ORCID: https://orcid.org/0009-0009-7877-7913)
Institutions
- Seoul National University (KR)
- University of California, San Francisco (US)
- University of San Francisco (US)
Publication Details
- Journal
- Thrombosis and Haemostasis
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1055/a-2679-6101
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Korea Health Industry Development Institute
- Ministry of Science and ICT, South Korea